A supplement to Skin & Allergy News and supported by Warner Chilcott.
This supplement to Skin & Allergy News is based on an expert roundtable as well as a presentation made at Skin Disease Education Foundation's 7th Annual Las Vegas Dermatology Seminar, a continuing medical education program, held November 10-12, 2006 in Las Vegas, Nevada.
• Current Topical Therapies for Psoriasis
• Efficacy of a Novel 2-Compound Ointment
• Safety Profile of a Novel 2-Compound Ointment
• Role of a 2-Compound Ointment in the Treatment Armamentarium for Psoriasis Vulgaris
Faculty/Faculty Disclosure Statement
Craig Leonardi, MD—Chair
Associate Clinical Professor of Dermatology
Saint Louis University
St. Louis, Missouri
Dr. Leonardi is a consultant for Abbott Laboratories, Amgen, Inc., Centocor, Inc., and Genentech, Inc. He has been an investigator for Abbott, Allergan, Inc., Altana, Inc., Amgen, Astellas Pharma US, Bristol-Myers Squibb, Centocor, CombinatoRx, Galderma Laboratories, L.P., Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, 3M Pharmaceuticals, and Vitae Pharmaceuticals. He is on the speakers' bureau for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott (US), Inc.
Jerry Bagel, MD
Director of the Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Assistant Professor of Dermatology
College of Physicians and Surgeons at Columbia University
New York, New York
Dr. Bagel speaks for Abbott, Amgen, Astellas, Genentech, Novartis, and Warner Chilcott. He is an investigator for Amgen, Astellas, Centocor, and Galderma.
Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Dr. Lebwohl is a consultant for or has pending consulting agreements for Abbott, Amgen, Astellas, Bristol-Myers Squibb, Centocor, Connetics Pharmaceuticals, Galderma, Genentech, Novartis, Pfizer, Inc., 3M, and Warner Chilcott. In the last 12 months, he has served as a speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, Novartis, PharmaDerm, 3M, and Warner Chilcott.
Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Dr. Gold is a principal investigator, consultant, and member of the speakers' bureau for Connetics, Galderma, and Warner Chilcott. She is a member of the speakers' bureau and a consultant for Genentech, and she is also a principal investigator for Astellas.
The participants discuss using the 2-compound ointment beyond the 4 weeks indicated by the product labeling.